期刊文献+

骨代谢标志物对非小细胞肺癌骨转移诊断的Logistic回归和受试者工作特征曲线评价 被引量:3

Diagnostic value of bone metabolic markers for bone metastasis of non-small cell lung cancer analyzed by Logistic regression combined with ROC curve
分享 导出
摘要 目的 通过Logistic回归模型及受试者工作特征(ROC)曲线评价骨钙素(BGP)、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)和Ⅰ型前胶原N-端前肽(PINP)检测在非小细胞肺癌(NSCLC)骨转移中的诊断价值.方法 选择65例晚期NSCLC患者,其中骨转移30例,无骨转移35例.采用电化学方法检测血清BGP、β-CTX和PINP水平.对筛选指标进行Logistic回归分析,建立Logistic回归方程,产生一组各单项预测值的新变量Y,对新变量及各单项指标进行ROC曲线分析.结果 NSCLC骨转移组患者血清β-CTX和PINP水平分别为(0.54±0.39)ng/ml、(103.64±81.86)ng/ml,均高于无骨转移组[(0.31±0.16)ng/ml和(48.37±27.76)ng/ml],差异有统计学意义(P<0.01);但BGP在两组间差异无统计学意义(P>0.05).β-CTX和PINP诊断NSCLC骨转移的ROC曲线下面积(AUC)分别为0.662和0.678.通过Logistic回归模型构建的新预测变量Y的AUC为0.761.结论 通过检测NSCLC患者血清β-CTX和PINP水平,应用Logistic回归和ROC曲线分析建立的统计学诊断模型能有效诊断NSCLC骨转移. Objective To investigate the diagnostic value of bone metabolic markers (BGP, β-CTX and PINP) for bone metastasis of non-small cell lung cancer (NSCLC) analyzed by Logistic regression combined with ROC curve.Methods A total of 65 patients with stage Ⅳ NSCLC were enrolled in this study.The patients were divided into two groups based on radiological imaging, includirg bone metastasis group (30 cases) and non-bone metastasis group (35 cases).The serum concentrations of BGP, β-CTX and PINP were measured by electrochemical method.Logistic regression and ROC curve were applied to analyze the data and evaluate the diagnostic values.Results The concentrations of β-CTX [(0.54±0.39) ng/ml] and PINP [(103.64±81.86) ng/ml] were significantly higher in bone metastasis group than those [(0.31±0.16) ng/ml and (48.37±27.76) ng/ml, respectively] in non-bone metastasis group (P 〈 0.01), while the level of BGP did not differ between two groups (P 〉 0.05).The area under the ROC curve (AUC) for β-CTX and PINP was 0.662 and 0.678, respectively.The AUC for the new predictive variables created by Logistic regression was 0.761.Conclusion Combined detection of β-CTX and PINP in the serum and application of Logistic regression combined with ROC curve analysis can increase diagnostic accuracy on bone metastasis of NSCLC.
作者 潘兴喜 杨文 杨画 唐武兵 陈永发 张永胜 Pan Xingxi, Yang Wen, Yang Hua, Tang Wubing, Chen Yongfa, Zhang Yongsheng( Department of Oncology, Nanhai Hospital Affiliated to Southern Medical University, Foshan 528200, China)
出处 《肿瘤研究与临床》 CAS 2016年第3期162-164,173共4页 Cancer Research and Clinic
基金 Medical Science and Technique Foundation of Foshan City of Guangdong Province,广东省佛山市医学类科技攻关项目
关键词 非小细胞肺 肿瘤转移 I型胶原羧基端肽β特殊序列 I型前胶原N-端前 Logistic模型 ROC曲线 Carcinoma, non-small-cell lung Neoplasms metastasis β-isomerized C-terminaltelopeptides of type I collagen N-terminal propeptide of type I procollage Logistic models ROC curve
作者简介 通信作者,杨文,Email:tangwbing@163.com
  • 相关文献

参考文献13

  • 1Coleman RE. Metastatic bone disease: clinical, features, pathophysiology and treatment strategies [ J ]. Cancer Treat Rev, 2001, 27 ( 3 ) : 165-176. DOI: 10.1053/ctrv.2000.0210. 被引量:1
  • 2Bae HM, Lee SH, Kim TM, et al. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis [ J ]. Lung Cancer, 2012, 77 (3) : 572-577. DOI: 10.1016/j.lungcan. 2012.05.094. 被引量:1
  • 3Seibel MJ. The use of molecular markers of bone turnover in the management of patients with metastatic bone disease [ J ]. Clin Endocrinol ( Oxf ), 2008, 68 ( 6 ) : 839-849. DOI: 10.1111/j. 1365- 2265.2007.03112.x. 被引量:1
  • 4Dane F, Turk HM, Sevinc A, et al. Markers of bone turnover in patients with lung cancer [ J ]. J Natl Med Assoc, 2008, 100 ( 4 ) : 425-428. 被引量:1
  • 5Francini F, Pascucci A, Bargagli G, et al. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer [ J ]. Int J Clin Oncol, 2011, 16 ( 3 ) : 264-269. DOI: 10.1007/s10147-010-0179-x. 被引量:1
  • 6Barnadas A, Manso L, de la Piedra C, et al. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study ( ZOMAR study ) [ J ]. Bone, 2014, 68: 32-40. DOI: 10.1016/j.bone.2014.07.036. 被引量:1
  • 7Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases [ J ]. Q J Nucl Med, 2001,45 ( 1 ) : 53-64. 被引量:1
  • 8Leeming D J, Koizumi M, Qvist P, et al. Serum N-terminal propeptide of collagen type I is associated with the number of bone metastases in breast and prostate cancer and correlates to other bone related markers [ J ]. Biomark Cancer, 2011, 3: 15-23. DOI: 10.4137/BIC.S6484. 被引量:1
  • 9Lumachi F, Santeufemia DA, Del CA, et al. Carboxy-terminal telopeptide ( CTX ) and amino-terminal propeptide ( PINP ) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer [ J ]. Anticancer Res, 2013, 33 ( 6 ) : 2593-2596. 被引量:1
  • 10Wang ZY, Yang C, Yang YM, et al. Clinical application value of bone turnover markers in non-small-cell lung cancer patients with bone metastases [ J ]. Chinese-German J Chn Oncol, 2011, 10 ( 2 ) : 81-84. DOI : 10.1007/s10330-011-0729-3. 被引量:1

二级参考文献14

  • 1SPSS Inc. SPSS Base 10.0 User's Guide[ M]. USA: SPSS Inc,1999. 431 - 434. 被引量:1
  • 2Chang MC, Chen JH, Liang JA, et al. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol, 2012, 19(3): 349-357. 被引量:1
  • 3Wang ZY, Yang C, Yang YM, et al. Clinical application value of bone turn- over markers in non-small-cell lung cancer patients with bone metastases. Chinese-GermanJ Clin Oncol, 2011, 10(2): 81-84. 被引量:1
  • 4Coleman RE. Glinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 2006, 12(20 Pt 2): 6243s-6249s. 被引量:1
  • 5Min JW, Um SW, Yim JJ, et al. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci, 2009, 24(2): 275-280. 被引量:1
  • 6Erturan S, Yaman iV[, Aydin G, et al. The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer. Chest, 2005, 127(2): 449-454. 被引量:1
  • 7Kong Q_Q Tu COa Dou Q Y, et al. Bone turnover markers in the detection of bone metastases in primary lung cancer. Sichuan Da Xue Xue Bao Yi Xue Ban, 2005, 36(3): 397-399. 被引量:1
  • 8Lund T, Abildgaard N, Andersen TL, et al. Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkalinephosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol, 2010, 84(5): 412-420. 被引量:1
  • 9Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab, 2003, 88(11): 5059-5075. 被引量:1
  • 10Leeming DJ, Koizumi M, Byrjalsen I, et al. The relative use of eight collag- enous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev, 2006, 15(1): 32-38. 被引量:1

共引文献119

同被引文献29

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈